These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25401784)

  • 41. [A placebo-controlled, double-blind, randomized trial of single daily dose of anti-muscarinic drug solifenacin succinate in patients with overactive bladder].
    Cardozo L; Lisec M; Milard R; Van Vierssen Trip O; Kuzmin I; Drogendijk TE; Huang AM
    Akush Ginekol (Sofiia); 2007; 46(5):55-7. PubMed ID: 17974184
    [No Abstract]   [Full Text] [Related]  

  • 42. Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.
    Herschorn S; Stothers L; Carlson K; Egerdie B; Gajewski JB; Pommerville P; Schulz J; Radomski S; Drutz H; Barkin J; Paradiso-Hardy F
    J Urol; 2010 May; 183(5):1892-8. PubMed ID: 20303119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
    Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
    Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.
    Hsiao SM; Lin HH; Kuo HC
    Neurourol Urodyn; 2014 Mar; 33(3):331-4. PubMed ID: 23494586
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
    Cardozo L; Castro-Diaz D; Gittelman M; Ridder A; Huang M
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):512-9. PubMed ID: 16625311
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Patient-reported outcome of solifenacin treatment among women experiencing urinary urgency and urgency incontinence.
    But I; Orešković S; Bratuš D; Šprem-Goldštajn M; Hlebič G
    Int J Gynaecol Obstet; 2014 Jan; 124(1):19-23. PubMed ID: 24135289
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.
    But I; Goldstajn MS; Oresković S
    Coll Antropol; 2012 Dec; 36(4):1347-53. PubMed ID: 23390832
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms.
    Brubaker L; FitzGerald MP
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jul; 18(7):737-41. PubMed ID: 17131169
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acupuncture versus solifenacin for treatment of overactive bladder and its correlation with urine nerve growth factor levels: a randomized, placebo-controlled clinical trial.
    Aydoğmuş Y; Sunay M; Arslan H; Aydın A; Adiloğlu AK; Şahin H
    Urol Int; 2014; 93(4):437-43. PubMed ID: 25033919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [PROSPECTS FOR THE TREATMENT OF IDIOPATHIC AND NEUROGENIC OVERACTIVE BLADDER].
    Kamalov AA; Korshunova ES; Popov GR; Khodyreva LA; Dudareva AA; Nizov AN
    Urologiia; 2015; (1):30-2, 34-5. PubMed ID: 26094383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence.
    Kelleher C; Cardozo L; Kobashi K; Lucente V
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Jun; 17(4):382-8. PubMed ID: 16283422
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
    Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
    Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status.
    Toglia MR; Ostergard DR; Appell RA; Andoh M; Fakhoury A; Hussain IF
    Int Urogynecol J; 2010 Jul; 21(7):847-54. PubMed ID: 20339833
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk factors for the failure of antimuscarinic treatment with solifenacin in women with overactive bladder.
    Serati M; Braga A; Siesto G; Sorice P; Cattoni E; Uccella S; Cromi A; Salvatore S; Ghezzi F
    Urology; 2013 Nov; 82(5):1044-8. PubMed ID: 24054438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
    Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
    Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
    Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
    Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Solifenacin succinate for the treatment of overactive bladder.
    Hoffstetter S; Leong FC
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):345-50. PubMed ID: 19331596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.
    Burger M; Betz D; Hampel C; Vogel M
    World J Urol; 2014 Aug; 32(4):1041-7. PubMed ID: 24135915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.